Asset Details
Do you wish to reserve the book?
The evolution of heat shock protein 90 C-terminal inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The evolution of heat shock protein 90 C-terminal inhibitors
Do you wish to request the book?
The evolution of heat shock protein 90 C-terminal inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The evolution of heat shock protein 90 C-terminal inhibitors
2026
Overview
Heat shock protein 90 (Hsp90) is a highly conserved molecular chaperone that regulates the maturation of various client proteins. Most therapeutic studies have focused on N-terminal Hsp90 inhibitors, but these are limited by dose-escalating toxicities that are caused by induction of the heat shock response. Leonard Neckers’discovery of novobiocin as a Hsp90 C-terminal inhibitor revealed an alternative mode to Hsp90 inhibition and established the C-terminal domain (CTD) as a therapeutic target. This review highlights recent advances in Hsp90 CTD inhibition and summarizes the evolution of novobiocin-based C-terminal inhibitors. Structure-activity relationship studies are discussed, demonstrating how medicinal chemistry optimization has produced CTD modulators with selective anti-proliferative or neuroprotective activities.
Publisher
Elsevier
We currently cannot retrieve any items related to this title. Kindly check back at a later time.